Nanoparticles for lupus

A Yale University group has designed a nanoparticle that selectively delivered an immunosuppressant to immune cells and improved survival in mouse models of lupus.¹ The nanoparticle delivery platform has been exclusively licensed to Immunova LLC, which is selecting an anti-inflammatory compound to take into the clinic.

Lupus is an autoimmune disease characterized by excessive production of proinflammatory cytokines and autoantibodies that cause damage to multiple tissues, including the kidneys, CNS, joints and skin...